MedDataX Logo

Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fed Male.

NCT ID: NCT02417844

Last Updated: 2020-04-17

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

34 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-04-30

Study Completion Date

2015-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Two tamsulosin HClformulations will be tested in fed state

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fasted Male.

NCT02417831

Prostatic Hyperplasia
COMPLETED PHASE1

Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia

NCT02245555

Prostatic Hyperplasia
COMPLETED

Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms

NCT01018511

Benign Prostatic Hyperplasia Lower Urinary Tract Symptoms
COMPLETED PHASE3

Study to Evaluate the Symptomatic Relief Effects of FLOMAX® in Patients With Signs and Symptoms of Benign Prostatic Hyperplasia

NCT02244242

Prostatic Hyperplasia
COMPLETED PHASE4

Tamsulosin Hydrochloride 0.4 mg Capsules Under Fasting Conditions

NCT01149746

Healthy
COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostatic Hyperplasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tamsulosin HCl

Group Type ACTIVE_COMPARATOR

Tamsulosin HCL

Intervention Type DRUG

Tamsulosin

Group Type ACTIVE_COMPARATOR

tamsulosin (Astellas)

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tamsulosin (Astellas)

Intervention Type DRUG

Tamsulosin HCL

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Health male volunteers 18 years and older

Exclusion Criteria

History of hypersensitivity or allergy to IMP or its excipients or any related medication
Minimum Eligible Age

18 Years

Maximum Eligible Age

64 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

527.89

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study To Compare 3 Different Formulations Of Tamsulosin At Steady State.
NCT00609596 COMPLETED PHASE1
Study to Investigate the Effect of Paroxetine Mediated CYP2D6 Inhibition on the Pharmacokinetics of Tamsulosin in Healthy Male Volunteers
NCT02264184 COMPLETED PHASE1
Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of Dutasteride and Tamsulosin Hydrochloride Relative to Co-administration of Dutasteride With Tamsulosin Hydrochloride in Healthy Male Subjects Under Fed and Fasted States
NCT02184585 COMPLETED PHASE1
FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia
NCT02244255 COMPLETED PHASE4
A Study With Combination Treatment (Tamsulosin Hydrochloride and Solifenacin Succinate) in Male Patients With LUTS/BPH
NCT00510406 COMPLETED PHASE2
A Study to Determine the Bioavailability of a Fixed Dose Combination Product of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) Relative to Co-administration of the Individual Components in Healthy Male Subjects of North East Asian and Non-Asian Ancestry.
NCT01254071 COMPLETED PHASE1
Actual Use Study of Tamsulosin in Men
NCT02573311 COMPLETED PHASE3
Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms
NCT02715024 COMPLETED PHASE4
Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin Hydrochloride (HCL) Combination Capsule in Fasted State
NCT02052713 COMPLETED PHASE1
Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male Subjects
NCT02509104 COMPLETED PHASE1
Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in Fed State
NCT02058576 COMPLETED PHASE1
(Phosphodiesterase 5 Inhibitors & α-blockers): Single Versus Combined Therapy in Benign Prostatic Hyperplasia
NCT05236634 UNKNOWN NA
Observational Study in Patients With Functional Benign Prostatic Hyperplasia Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin)
NCT02244320 COMPLETED
Study to Investigate the Effect of Ketoconazole Mediated CYP3A4 Inhibition on Pharmacokinetics of Tamsulosin in Healthy Male Volunteers
NCT02264171 COMPLETED PHASE1
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia
NCT00970632 COMPLETED PHASE3
Study to Characterise the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms
NCT02245490 COMPLETED PHASE4
Tamsulosin Hydrochloride 0.4 mg Capsules Under Fed Conditions
NCT01149733 COMPLETED PHASE1
Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms
NCT01021332 COMPLETED PHASE3
FLOMAX® Versus Placebo, in Male Patients With Acute Urinary Retention Related to Benign Prostatic Hyperplasia (BPH)
NCT02244294 COMPLETED PHASE2
Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Solifenacin and Tamsulosin
NCT02180997 COMPLETED PHASE1
Bioequivalence - Duodart Against Avodart & Omnic
NCT01657851 COMPLETED PHASE1
A Study of Tadalafil in Benign Prostatic Hyperplasia
NCT01183650 COMPLETED PHASE1
A Study To Compare Giving AVODART And FLOMAX Together Or In A Combination Capsule In The Fed And Fasted State
NCT00537654 COMPLETED PHASE1
A Study to Evaluate the Tolerability and Efficacy of Tamsulosin 0.4mg OCAS Formulation in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2mg Conventional Formulation
NCT02180789 COMPLETED PHASE4
Pilot Study Investigating Safety and Efficacy of Tadalafil as Treatment for Benign Prostatic Hyperplasia (BPH) in Asian Men
NCT00540124 COMPLETED PHASE2